CORDIS
EU research results

CORDIS

English EN
Breast CAncer STratification: understanding the determinants of risk and prognosis of molecular subtypes

Breast CAncer STratification: understanding the determinants of risk and prognosis of molecular subtypes

Objective

Breast tumours are heterogeneous, and result from the complex interplay of multiple lifestyle/environmental and genetic risk factors. Through the EU-funded COGS project, we have identified a large number of germline variants that influence the risk of breast cancer. In combination, these variants can identify women at wide ranges of genetic risk, even in the absence of family history of breast cancer. Given that breast cancer is not one disease, it is now essential to better understand how risk factors act together to influence the development of pathologic-molecular subtypes of breast cancer.
The aim of B-CAST is to identify women at moderate to high risk of breast cancer, the subtype of cancer that is most likely to develop and the prognosis of that particular subtype. This will be accomplished through large-scale pathologic-molecular analyses of over 20,000 breast tumours, and the integration of these data with unique resources from existing consortia, including germline, lifestyle/environmental, mammographic breast density, pathologic and clinical data. This information will inform the development of risk prediction and prognostication models that will be validated in longitudinal cohorts and clinical studies, and incorporated into online tools. We will also disseminate this knowledge to relevant stakeholders, and evaluate how to translate it into risk-stratified public health and clinical strategies.
The current challenge for optimised prevention, early detection, and treatment decisions for breast cancer is understanding the genetic and lifestyle determinants of risk and prognosis of molecular subtypes. B-CAST will add to this understanding and will have immediate application with benefits to women by providing validated risk and prognostication tools. This will empower women and doctors with knowledge to tailor strategies for prevention and treatment. Ultimately, this work should result in reductions in the occurrence, morbidity and mortality of this disease.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS

Address

Plesmanlaan 121
1066 Cx Amsterdam

Netherlands

Activity type

Research Organisations

EU Contribution

€ 925 687,50

Participants (12)

Sort alphabetically

Sort by EU Contribution

Expand all

THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL

United Kingdom

EU Contribution

€ 383 306,25

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 1 056 118,75

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 350 000

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG

Germany

EU Contribution

€ 268 750

UNIVERSIDAD DE SANTIAGO DE COMPOSTELA

Spain

EU Contribution

€ 399 000

FUNDACIO PARC CIENTIFIC DE BARCELONA

Spain

VIB

Belgium

EU Contribution

€ 63 750

FOUNDATION FOR GENOMICS & POPULATION HEALTH

United Kingdom

EU Contribution

€ 228 618,75

UNIVERSITE LAVAL

Canada

QUEENSLAND INSTITUTE OF MEDICAL RESEARCH

Australia

HARVARD GLOBAL RESEARCH AND SUPPORT SERVICES INC.

United States

FUNDACIO CENTRE DE REGULACIO GENOMICA

Spain

EU Contribution

€ 2 308 125

Project information

Grant agreement ID: 633784

Status

Ongoing project

  • Start date

    1 September 2015

  • End date

    31 August 2020

Funded under:

H2020-EU.3.1.1.

  • Overall budget:

    € 6 120 856,25

  • EU contribution

    € 5 983 356,25

Coordinated by:

STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS

Netherlands